Abbott Laboratories

NYSE: ABT
$116.80
-$0.93 (-0.8%)
Closing Price on November 6, 2024

ABT Articles

Alere absolutely skyrocketed in Monday’s regular session following the announcement that it will be acquired by Abbott Laboratories.
January 28, 2016: Here are four stocks trading with heavy volume among 222 equities making new 52-week lows today. Juniper Networks Inc. (NYSE: JNPR) dropped more than 17% on Thursday to post a new...
Thursday's top analyst calls include Alcoa, GoPro, MetLife, Netflix, SUPERVALU, Walt Disney, Williams Companies and Yelp.
One good plan for stockholders who are seeing gains evaporate is to rotate to a more defensive sector. Large cap pharmaceutical stocks totally fit the bill.
These companies all provide drugs and medical devices that help hundreds of thousands of people daily lead a better life. They make good sense for conservative portfolios looking for income and...
In what still may be a pricey market, these stock make good sense for growth accounts looking to add value, and they are far safer than high-volatility momentum stocks.
Brokerage firm Jefferies has released its top pharmaceutical picks for the coming year and what to expect.
Monday's top analyst upgrades, downgrades and initiations include Abbott Labs, Bluebird Bio, Chipotle, Eli Lilly, Ferrari and Wells Fargo.
Despite the howling from political candidates trying to make the top drug-makers their whipping boy in populist campaign efforts, the need and demand for pharmaceuticals will only continue. This...
Friday's top analyst upgrades, downgrades and initiations include Abbott Labs, BioMarin Pharmaceutical, CBS, Cisco, GameStop, Petrobras, Sirius XM, SunPower and Yelp.
24/7 Wall St. screened the Merrill Lynch research universe for pharmaceutical stocks paying solid dividends that are rated Buy, and found four outstanding companies.
Wednesday's top analyst upgrades, downgrades and initiations include Adobe Systems, FireEye, Lululemon Athletica, Nu Skin, Rio Tinto, Tesla Motors and BHP Billiton.
A new report from Deutsche Bank makes the case that the selling in health care stocks is way overdone, and the proverbial baby is being tossed out with the bath water.
One positive from the hammering the pharmaceutical stocks have taken is the Merrill Lynch analysts say investors have been given a golden opportunity to buy the top companies at much better prices.
24/7 Wall St. screened the Merrill Lynch health care universe and found four pharmaceutical stocks rated Buy with outstanding short-term and long-term potential.